CHMP Backs First-in-Class Drug Emicizumab for Hemophilia A CHMP Backs First-in-Class Drug Emicizumab for Hemophilia A

The CHMP recommended marketing authorization for emicizumab. a first-in-class drug for patients of all ages with hemophilia A with factor VIII inhibitors.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news